Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto¹, Negin Shojaee ¹, Ravi Shankar P Singh ¹, Zorayr Manukyan ², Jessica Mancuso ¹, Elena Peeva ¹, Michael Vincent ¹ and Jean Beebe ¹, ¹Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, ²Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
Abstract Number: 42 • 2019 ACR/ARP Annual Meeting
Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
Sheila Arvikar¹, Hatice Hasturk ², Klemen Strle ¹, Marcy Bolster ¹, Deborah Collier ¹, Alpdogan Kantarci ² and Allen Steere ¹, ¹Massachusetts General Hospital, Boston, MA, ²Forsyth, Cambridge, MA
Background/Purpose: Periodontitis and immune responses to periodontal pathogens such as Porphyromonas gingivalis (Pg) are associated with rheumatoid arthritis (RA) but the mechanisms underlying these connections…
Abstract Number: 177 • 2019 ACR/ARP Annual Meeting
Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal
Mariana Luís¹, Salomé Garcia ², Francisca Guimarães ³, Manuel António ⁴, Ana Fernandes ⁵, Filipe Araújo ⁶, Rita Cunha ⁷, Maura Couto ⁸, Ana Pinto ⁹, Lígia Silva ¹⁰, Margarida Cruz ¹¹, Jose Pereira da Silva ¹² and Catia Duarte ¹³, ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Centro Hospitalar São João, Porto, Portugal, ³Centro Hospitalar do Alto Minho, Ponte de Lima, Portugal, ⁴Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Centro Hospitalar do Algarve, Faro, Portugal, ⁶Hospital Ortopédico de Sant’Ana, Lisboa, Portugal, ⁷Centro Hospitalar Baixo Vouga, Aveiro, Portugal, ⁸Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁹Unidade Local de Saúde da Guarda, Guarda, Portugal, ¹⁰Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹¹Centro Hospitalar do Oeste, Caldas da Rainha, Portugal, ¹²Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, ¹³Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal
Background/Purpose: Work disability is a common consequence of Rheumatoid Arthritis (RA) with economic implications for both the patient and society. Scarce information is available on…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
Abstract Number: 463 • 2019 ACR/ARP Annual Meeting
High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis
Cleandro Albuquerque¹, Ana Reis ², Ana Santos ³, Claiton Brenol ⁴, Ivanio Pereira ⁵, Karina Bonfiglioli ⁶, Manoel Bertolo ⁷, Maria Guimarães ⁸, Maria Sauma ⁹, Paulo Filho ¹⁰, Rina Giorgi ¹¹, Sebastião Radominski ¹², Licia Mota ¹ and Geraldo Castelar ³, ¹UnB, Brasília, Brazil, ²UniCeub, Brasília, Brazil, ³UERJ, Rio de Janeiro, Brazil, ⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, ⁵UFSC, Florianópolis, Brazil, ⁶Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁷University of Campinas, Campinas, Brazil, ⁸UFMG, Belo Horizonte, Brazil, ⁹UFPA, Belém, Brazil, ¹⁰USP, São Paulo, Brazil, ¹¹Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ¹²Universidade Federal do Paraná, Curitiba, Brazil
Background/Purpose: The rheumatoid factors (RF) have established roles in rheumatoid arthritis (RA) diagnosis, prediction of disease onset and drug response, and in classifying patients as…
Abstract Number: 499 • 2019 ACR/ARP Annual Meeting
The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis
Barbara Mascialino¹, Linda Mathsson-Alm ¹, Maryam Poorafshar ¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The detection of antibodies to cyclic citrullinated peptides (anti-CCP) may occur long before the onset of rheumatoid arthritis (RA) symptoms.Several versions of CCP antigen…
Abstract Number: 546 • 2019 ACR/ARP Annual Meeting
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
René Toes¹, Thomas Lehman ², Joshua Bryson ³, Amy Min Kim ², Sandhya Balachandar ², Sumanta Mukherjee ², Michael Maldonado ², Sean Connolly ² and Thomas Huizinga ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Princeton
Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
Abstract Number: 1200 • 2019 ACR/ARP Annual Meeting
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital
Judith Aniekwena¹, Titilope Olanipekun ² and Valery Effoe ², ¹Morehouse School of Medicine, Atlanta, GA, ²Morehouse School of Medicine, Atlanta
Background/Purpose: Influenza infection constitutes a significant cause of morbidity and mortality in patients living with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The risk…
Abstract Number: 1348 • 2019 ACR/ARP Annual Meeting
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Louis Bessette¹, Maxime Dougados ², Eduardo Mysler ³, Mark Genovese ⁴, Cassandra Kinch ⁵, Kenneth Kwok ⁶, Tatjana Lukic ⁶, Tanya Girard ⁵, Pierre-Alexandre Landry ⁵ and Ronald van Vollenhoven ⁷, ¹Laval University, Quebec City, QC, Canada, ²Cochin Hospital, Paris, France, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Stanford University, Stanford, CA, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. In clinical trials, standard criteria for measuring treatment efficacy in patients (pts) with…
Abstract Number: 1378 • 2019 ACR/ARP Annual Meeting
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
Vibeke Strand¹, Jerome Msihid ², Toshio Kimura ³, Anita Boyapati ³, Gregory St John ⁴ and Wenhui Wei ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Sanofi, Chilly-Mazarin, France, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients. However,…
Abstract Number: 1412 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study
Stanley Cohen¹, Janet Pope ², Boulos Haraoui ³, Eduardo Mysler ⁴, Annette Diehl ⁵, Tatjana Lukic ⁶, Shixue Liu ⁷, Lori Stockert ⁵, Sujatha Menon ⁸ and Edward Keystone ⁹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Western University, London, ON, Canada, ³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Shanghai, China (People's Republic), ⁸Pfizer Inc, Groton, CT, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The tofacitinib modified-release (MR) 11 mg once daily (QD) formulation was first…
Abstract Number: 1765 • 2019 ACR/ARP Annual Meeting
Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis
Malin Erlandsson ¹, Karin Andersson ¹, Nisha Nair ², Anastasius Damdimopoulos ³, Sofia Silfverswärd ¹, Rille Pullerits ¹, Anne Barton ² and Maria Bokarewa¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ³Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden
Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].